Men who take statins for at least 11 months might be at lower risk for low- and high-Gleason grade prostate cancer than men who do not take the cholesterol-lowering drugs, according to a recent study (Cancer Medicine Oct. 8, 2019 [Epub ahead of print]).
The risk reduction associated with statin use was higher for higher-risk prostate cancer, according to study author Kai Wang, MD, PhD, of Harvard T.H. Chan School of Public Health, Boston.
Because this was an observational study, whether statins can be used for prostate cancer prevention or treatment in clinic remains uncertain before more clinical trial studies have been conducted, said Dr. Wang, working with Mattia Prosperi, MEng, PhD, and co-authors.
Evidence suggests statins might act chemo-preventatively against prostate cancer because the drugs lower serum and tissue cholesterol. That disrupts cellular lipid rafts, leading to reduced raft-dependent signaling and cell proliferation, the authors wrote.
Yet studies looking at how using statins might impact prostate cancer risk have had mixed results. This study is among the largest longitudinal studies to analyze the relationship between statin use and Gleason score-specific prostate cancer, ...